Ixabepilone/Bevacizumab Improves PFS and OS in Platinum-Resistant/Refractory Ovarian Cancer
March 19th 2024Combining ixabepilone with bevacizumab generated improved survival rates and high response rates compared with ixabepilone monotherapy in platinum-resistant or platinum-refractory ovarian cancer.
Responses With Pirtobrutinib Still High Even With Acquired Resistance in Relapsed CLL/SLL
December 13th 2023Responses on the non-covalent BTK inhibitor pirtobrutinib remained high in patients with relapsed chronic lymphocytic leukemia who expressed frequent baseline BTK mutations, according to a genomic analysis of the phase 1/2 BRUIN trial.
BGB-16673 Shows Responses With a Manageable Safety Profile Across R/R B-Cell Malignancies
December 12th 2023The novel BTK degrader BGB-16673 was well tolerated; produced meaningful and rapid clinical responses; and demonstrated on-target effects in patients with relapsed/refractory B-cell malignancies.
Real-World Data Suggest Favorable Outcomes With Post-Axi-Cel Administration in R/R LBCL
December 10th 2023Although the use of bridging therapy prior to treatment with axicabtagene ciloleucel did not improve efficacy or safety outcomes for patients with relapsed/refractory large B-cell lymphoma, responses to bridging therapy may be prognostic of favorable outcomes after axi-cel administration.
Survival Disparities Shown With BluePrint and MammaPrint Subtyping in HR+/HER2– Breast Cancer
December 7th 2023Accurately stratifying hormone receptor–positive, HER2-negative breast cancer using BluePrint and MammaPrint assays demonstrated comparable 3-year recurrence-free survival rates between Black and White patients despite disparities in the distribution of molecular subtypes.
Comparative Efficacy, Tolerability With RP2D of Belzutifan in LITESPARK-013 Trial for ccRCC
November 11th 2023Results unveiled at the 2023 International Kidney Cancer Symposium revealed that patients with advanced clear cell renal cell carcinoma in the 200-mg dose group achieved an overall response rate of 23.1% based on blinded independent central review.